23andMe Co-Founder’s Bankruptcy Sale Fight Prompts Objections

Regeneron Pharmaceuticals and a privacy ombudsman are raising concerns over a push by 23andMe’s co-founder to challenge the drug developer’s $256 million bid for the bankrupt genetic-testing firm’s DNA data bank.

23andMe co-founder Anne Wojcicki’s TTAM Research Institute violated sale procedures by submitting new bids after an auction closed, Regeneron told the US Bankruptcy Court for the Eastern District of Missouri in a filing Thursday.

TTAM, which is looking to reopen the auction, should also be prevented from using discovery to gain insight into Regeneron’s bidding strategy and internal deliberations, Regeneron said.

“Any litigation and discovery should be carefully ...